Inflammatory arthritis is a group of conditions in which the immune system attacks the joints, causing pain, swelling, and stiffness that can worsen over time if untreated. Unlike osteoarthritis, which results from physical wear and tear on cartilage, inflammatory arthritis starts as an internal immune system malfunction. The distinction matters because the causes, symptoms, and treatments are fundamentally different.
How It Differs From Osteoarthritis
Osteoarthritis develops when the cartilage cushioning a joint breaks down over time, typically from aging, injury, or repetitive stress. It tends to affect weight-bearing joints like the hips, knees, and shoulders, and pain usually flares after physical activity.
Inflammatory arthritis works in the opposite direction. The immune system targets healthy tissue inside the joint, triggering inflammation that then damages cartilage and bone. It favors the small joints of the hands and feet, and stiffness is worst first thing in the morning or after long periods of rest. Morning stiffness lasting longer than one hour is a hallmark sign of an inflammatory process rather than a mechanical one.
Both conditions involve inflammation, which is part of what makes them confusing. In osteoarthritis, cartilage loss eventually triggers a secondary inflammatory response. But in inflammatory arthritis, inflammation is the starting point, not a consequence. That distinction shapes everything about how the disease is managed.
The Main Types
Inflammatory arthritis is an umbrella term covering several distinct conditions:
- Rheumatoid arthritis (RA) is the most common form. It’s a chronic autoimmune disease that typically affects the hands, wrists, and feet symmetrically, meaning the same joints on both sides of the body. In 2019, roughly 18 million people worldwide were living with RA, about 70% of them women. The typical onset occurs in the sixties, though it can start at any age.
- Psoriatic arthritis develops in some people with the skin condition psoriasis. It can affect any joint and often causes swelling in entire fingers or toes, sometimes called “sausage digits.”
- Ankylosing spondylitis primarily targets the spine and the joints where the spine connects to the pelvis, leading to stiffness and, in severe cases, fusion of vertebrae.
- Gout and pseudogout result from crystal deposits in the joints rather than autoimmune activity, but they produce intense inflammatory flares that fall under this category.
- Arthritis linked to connective tissue diseases like lupus, scleroderma, and Sjögren’s syndrome.
- Infection-associated arthritis triggered by conditions like Lyme disease, rheumatic fever, or reactive arthritis following a bacterial infection.
What Happens Inside the Joint
In a healthy joint, a thin lining called the synovial membrane produces fluid that lubricates and nourishes cartilage. In inflammatory arthritis, immune cells flood this membrane and trigger a cascade of chemical signals that sustain and amplify inflammation. White blood cells migrate into the joint space, releasing molecules that recruit even more immune cells.
Over time, this persistent inflammation causes the synovial membrane to thicken dramatically, forming an aggressive tissue called pannus. Pannus grows over and into the cartilage and underlying bone, gradually eroding them. This is why early treatment is so important: once bone and cartilage are destroyed, the damage is largely irreversible. The goal of modern treatment is to stop this process before structural damage accumulates.
Symptoms Beyond the Joints
Inflammatory arthritis is a systemic disease, meaning it can affect far more than joints. Fatigue is one of the most common complaints, often disproportionate to visible joint involvement. Anemia is among the most frequent extra-joint findings and contributes to that persistent tiredness.
The eyes are another common target. At least 10% of people with RA develop dry eyes from a condition called keratoconjunctivitis sicca, which overlaps with Sjögren’s syndrome. Less commonly, inflammation can affect the white of the eye itself, causing redness and deep pain.
Cardiovascular risk is a serious long-term concern. People with RA are more prone to atherosclerosis, the buildup of plaque in artery walls. Women with RA face roughly twice the risk of heart attack compared to women without it. For those who have had the disease for 10 years or more, that risk triples. The lungs, kidneys, nervous system, and skin can also be involved, with pulmonary complications and Sjögren’s syndrome each appearing in 6 to 10% of cases.
How It’s Diagnosed
No single test confirms inflammatory arthritis. Diagnosis relies on a combination of symptoms, physical examination, blood work, and imaging.
During a physical exam, the two key signs of joint inflammation are visible swelling and pain when the joint is pressed or moved. The swelling has a soft, fluid-filled quality caused by excess synovial fluid and thickened tissue along the joint margins. Redness and warmth are less reliably present than you might expect, so their absence doesn’t rule out inflammation.
Blood tests look for two things: evidence of active inflammation and immune markers that suggest a specific diagnosis. Inflammation is measured through markers like C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR, sometimes called “sed rate”), both of which tend to be elevated when inflammation is active. For rheumatoid arthritis specifically, doctors check for rheumatoid factor and anti-CCP antibodies. These antibodies are found in many RA patients, but not all. Some people with confirmed RA test negative for both, a form called “seronegative” RA.
Imaging, particularly ultrasound and MRI, can reveal synovial thickening, joint fluid, and early bone erosion before changes show up on standard X-rays.
Treatment and What to Expect
The central principle of treating inflammatory arthritis is early, aggressive control of inflammation. The longer the disease goes unchecked, the more joint damage accumulates. Modern treatment follows a “treat-to-target” approach, meaning medications are adjusted until inflammation is driven into remission or as close to it as possible.
The backbone of treatment is a class of drugs called disease-modifying antirheumatic drugs, or DMARDs. These don’t just manage pain; they slow or stop the immune process that drives joint destruction. The most widely used conventional DMARD is methotrexate, typically taken once a week as a pill or injection. Other options in this category include sulfasalazine, hydroxychloroquine, and leflunomide. These medications take several weeks to reach their full effect, so short-term relief with anti-inflammatory drugs or low-dose steroids is common in the early months.
When conventional DMARDs aren’t enough, biologic medications offer a more targeted approach. Biologics are engineered proteins that block specific immune signals driving inflammation. The largest group targets a molecule called TNF, a key driver of the inflammatory cascade. Other biologics block different pathways in the immune response. A newer category, called targeted synthetic DMARDs, works by interrupting signaling inside immune cells rather than blocking proteins outside them. These are taken as pills rather than injections.
People with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis almost always need at least one disease-modifying medication for long-term management. Treatment is ongoing, and most people remain on some form of therapy even after achieving remission, because stopping medication frequently leads to flares.
Why Early Treatment Matters
Joint damage from inflammatory arthritis can begin within months of the first symptoms. Studies consistently show that starting disease-modifying treatment within the first few months of symptom onset leads to significantly better outcomes than waiting. People treated early are more likely to achieve full remission and less likely to develop the kind of structural damage that limits hand function or mobility.
The practical takeaway is that persistent joint swelling, morning stiffness lasting more than an hour, and unexplained fatigue deserve prompt medical evaluation. These symptoms often develop gradually, and it’s common for people to attribute them to aging or overuse before the pattern becomes clear. Inflammatory arthritis is highly treatable with current medications, but the window for preventing irreversible damage is relatively narrow.